Models | Subgroup | Study number (case/control) | OR (95% CI) | z | P |
---|---|---|---|---|---|
Heterozygotic model (AG vs. AA) | Lung cancer | 19 (5004/9162) | 0.86 (0.76–0.97) | 2.46 | 0.014 |
LSCC | 3 (878/19,47) | 0.79 (0.64–0.97) | 2.23 | 0.026 | |
NSCLC | 3 (928/1766) | 0.78 (0.62–0.97) | 2.19 | 0.029 | |
LA | 3 (968/1947) | 0.84 (0.67–1.06) | 1.45 | 0.147 | |
Breast cancer | 6 (2530/2940) | 1.04 (0.79–1.38) | 0.30 | 0.761 | |
Digestive system cancer | 18 (4038/6811) | 1.05 (0.85–1.30) | 0.48 | 0.634 | |
Esophageal cancer | 10 (2515/4002) | 0.93 (0.70–1.23) | 0.52 | 0.602 | |
ESCC | 4 (1136/2239) | 0.88 (0.58–1.34) | 0.59 | 0.554 | |
Gastric cancer | 4 (828/1495) | 1.14 (0.71–1.82) | 0.54 | 0.589 | |
Colorectal cancer | 3 (593/1021) | 1.46 (1.02–2.11) | 2.04 | 0.041 | |
Reproductive system cancer | 5 (1429/1756) | 1.02 (0.81–1.28) | 0.17 | 0.867 | |
Endometrial cancer | 3 (1182/1244) | 0.94 (0.72–1.23) | 0.45 | 0.656 | |
Head and neck cancer | 4 (886/2289) | 0.95 (0.74–1.22) | 0.39 | 0.694 | |
Skin cancer | 6 (3874/3826) | 1.18 (1.02–1.36) | 2.18 | 0.029 | |
Skin BCC | 3 (1852/1669) | 1.14 (0.92–1.42) | 1.17 | 0.241 | |
Dominant model (AG + GG vs. AA) | Lung cancer | 19 (5004/9162) | 0.87 (0.77–0.98) | 2.30 | 0.021 |
LSCC | 3 (878/19,47) | 0.80 (0.63–1.01) | 1.86 | 0.062 | |
NSCLC | 3 (928/1766) | 0.83 (0.64–1.07) | 1.46 | 0.145 | |
LA | 3 (968/1947) | 0.88 (0.71–1.09) | 1.20 | 0.230 | |
Breast cancer | 6 (2530/2940) | 1.04 (0.78–1.40) | 0.28 | 0.782 | |
Digestive system cancer | 18 (4038/6811) | 1.14 (0.89–1.44) | 1.04 | 0.297 | |
Esophageal cancer | 10 (2515/4002) | 1.01 (0.72–1.43) | 0.06 | 0.953 | |
ESCC | 4 (1136/2239) | 0.99 (0.60–1.65) | 0.02 | 0.982 | |
Gastric cancer | 4 (828/1495) | 1.16 (0.71–1.89) | 0.58 | 0.561 | |
Colorectal cancer | 3 (593/1021) | 1.54 (1.08–2.20) | 2.41 | 0.016 | |
Reproductive system cancer | 5 (1429/1756) | 1.07 (0.87–1.32) | 0.63 | 0.528 | |
Endometrial cancer | 3 (1182/1244) | 1.01 (0.75–1.37) | 0.09 | 0.926 | |
Head and neck cancer | 4 (886/2289) | 1.02 (0.81–1.29) | 0.16 | 0.873 | |
Skin cancer | 6 (3874/3826) | 1.27 (1.10–1.45) | 3.36 | 0.001 | |
Skin BCC | 3 (1852/1669) | 1.25 (1.00–1.56) | 1.98 | 0.048 | |
Recessive model (GG vs. AA + AG) | Lung cancer | 19 (5004/9162) | 0.99 (0.90–1.08) | 0.31 | 0.755 |
LSCC | 3 (878/19,47) | 0.97 (0.81–1.16) | 0.35 | 0.726 | |
NSCLC | 3 (928/1766) | 1.08 (0.72–1.62) | 0.39 | 0.700 | |
LA | 3 (968/1947) | 1.05 (0.87–1.27) | 0.51 | 0.613 | |
Breast cancer | 6 (2530/2940) | 0.98 (0.77–1.24) | 0.20 | 0.842 | |
Digestive system cancer | 20 (4340/7157) | 1.26 (1.03–1.54) | 2.24 | 0.025 | |
Esophageal cancer | 10 (2515/4002) | 1.28 (0.89–1.83) | 1.32 | 0.186 | |
ESCC | 4 (1136/2239) | 1.35 (0.81–2.27) | 1.15 | 0.249 | |
Gastric cancer | 4 (828/1495) | 1.05 (0.79–1.40) | 0.33 | 0.739 | |
Colorectal cancer | 5 (895/1367) | 1.22 (0.95–1.56) | 1.59 | 0.111 | |
Reproductive system cancer | 5 (1429/1756) | 1.16 (1.00–1.34) | 1.91 | 0.056 | |
Endometrial cancer | 3 (1182/1244) | 1.18 (0.97–1.44) | 1.65 | 0.098 | |
Head and neck cancer | 4 (886/2289) | 1.15 (0.94–1.41) | 1.39 | 0.165 | |
Skin cancer | 6 (3874/3826) | 1.20 (1.09–1.31) | 3.93 | < 0.001 | |
Skin BCC | 3 (1852/1669) | 1.23 (1.07–1.40) | 2.99 | 0.003 |